Dublin, July 07, 2017 -- Research and Markets has announced the addition of the "Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH): 2-Day Workshop by Dr. Huber" conference to their offering.
This 2-day workshop will give attendees the background to understand the requirements, and even more significantly, it will focus on strategies and provide tools to implement most critical requirements. It will also provide templates and examples to develop inspection ready documentation. Interactive workshop exercises will be dispersed into and between the presentations. About 50% of the total time will be dedicated to practical sessions with real life examples. After the course a variety of tools such as SOPs, validation examples and checklists will be readily available on a dedicated website that can be used to easily implement what attendees have learned in the course.
Analytical methods and procedures should be validated to ensure reliability, consistency and accuracy of analytical data. Compendial methods should be verified to demonstrate the suitability of laboratories to successfully run the method and when methods are transferred between laboratories successful transfer should be demonstrated through testing. In case a laboratory wants to use an alternative method instead of a compendial method, equivalency of the alternative method to the compendial method should be demonstrated.
Method validation recently got highest attention from regulatory agencies and industry task forces. For example, FDA and EMA released guidelines on method validation and transfer, and USP has proposed new approaches chapters for integrated validation, verification and transfer of analytical procedures, for equivalency testing and for statistical evaluation.
Learning Objectives:
- Learn about the regulatory background and requirements for validation of analytical methods and procedures
- Learn how to plan, execute and document development and validation of methods developed in-house
- Be able to explain the different requirements for validation, verification and transfer of analytical procedures
- Understand the principles of validating methods developed in-house, verification of compendial methods, transfer of analytical procedures and demonstrating equivalency to compendial methods
- Be able to explain your company's strategy for method validation, verification, transfer and equivalency testing
- Be able to select test parameters, test conditions and acceptance criteria for different analytical tasks
- Be able to justify and document decisions about revalidation after method changes
- Be able to define and demonstrate FDA and EU compliance to auditors and inspectors
- Be able to develop inspection ready documentation during on-going routine operation
- Understand statistical evaluation of validation test results
- Understanding what questions will be asked during audits and inspections and how to answer them
Who Should Attend:
- QA managers and personnel
- Quality control
- Method development
- Analytical chemists
- Validation specialists
- Laboratory managers and supervisors
- Regulatory affairs
- Training departments
- Documentation departments
- Consultants
For more information about this conference visit https://www.researchandmarkets.com/research/c7xxpg/validation
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Healthcare Services, Pharmaceutical Manufacturing


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Apple Turns 50: From Garage Startup to AI Crossroads
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
First Western Ship Transits Strait of Hormuz Since Iran War Began 



